The EMBRACA clinical trial (NCT01945775) (Study Details A Study Evaluating Talazoparib BMN 673, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation EMBRACA Study ClinicalTrials.gov, 2023) evaluated the safety and efficacy of the PARP inhibitor talazoparib (BMN 673) in patients with advanced and HER2-negative metastatic breast cancer with a BRCA1/2 mutation. The gene discussed is BRCA1; the disease is breast cancer.